1. Introduction {#sec1}
===============

Oral dysgeusia is defined as a gustatory disturbance relating to a distorted taste perception, or to a persistent taste sensation in the absence of stimulation \[[@B1]\], and can be very distressing for the patient. Patients with taste disturbances are commonly referred to and investigated within Oral Medicine Departments in the UK. Identifiable causes of dysgeusia can include local factors, drugs, systemic disease, and peripheral or central neurological conditions; see [Table 1](#tab1){ref-type="table"} \[[@B1]--[@B5]\].

Local factors influencing taste include infections of the oral cavity, such as candidiasis or dental abscess, trauma, or hyposalivation \[[@B1]--[@B3]\]. Over 250 drugs have been associated with oral dysgeusia, of which the most common are outlined in [Table 1](#tab1){ref-type="table"} \[[@B3]--[@B5]\]. Dysgeusia can also be a manifestation of a systemic disease such as an underlying haematinic deficiency, diabetes mellitus, Crohn\'s disease, or Sjögren\'s syndrome \[[@B1], [@B3]\]. Rarely, damage to the peripheral or central nervous system can be the cause. Tumours affecting the cerebellopontine angle, such as a schwannoma or meningioma, can cause taste disturbances. Central neurological causes such as ischaemia, haemorrhage, or demyelination affecting the gustatory pathway in the brain, or temporal lobe epilepsy, also require exclusion \[[@B1]\].

In a significant number of cases, the taste disturbance cannot be attributed to an identifiable cause and therefore a diagnosis of idiopathic oral dysgeusia is made. Although altered taste is a rare symptom of vestibular schwannoma, this case illustrates the need for a high index of clinical suspicion when assessing patients with seemingly low level symptoms, such as oral dysgeusia.

2. Case Presentation {#sec2}
====================

2.1. History {#sec2.1}
------------

A fifty-year-old male patient was referred to the Oral Medicine Department by his General Dental Practitioner with a primary complaint of an altered taste. The taste disturbance had been affecting the patient for six months and manifested as a constant salty taste. His General Medical Practitioner had empirically prescribed omeprazole to exclude gastric oesophageal reflux disease as a potential cause. However, this was ineffective and therefore the patient had discontinued the treatment.

Additionally, the patient also complained of a cracked tongue surface and intermittent numbness of his lower left lip and chin. He had experienced three episodes of facial hypoesthesia affecting the mandibular division of the left trigeminal nerve, which had all been self-limiting and resolved spontaneously.

Medical history was clear except for tinnitus and a feeling of fullness affecting the left ear for the past three years. This had been diagnosed by the General Medical Practitioner as Eustachian tube dysfunction and treated with fluticasone nasal spray. This had no benefit in relieving the symptoms and was discontinued. The patient therefore took no regular medication.

Socially, the patient was a semiretired office based worker. He was a nonsmoker and had a low alcohol intake.

2.2. Examination {#sec2.2}
----------------

Cranial nerve examination at the initial clinic appointment did not reveal any sensory disturbance along the trigeminal nerves or motor deficit of the facial nerves. The eyes were unaffected, with no lacrimation abnormalities identified. Swallow and phonation were not affected. The uvula was not deviated, and the movement of the palate and tongue was normal. Extra oral examination of the head and neck showed normal anatomy, with no facial swelling and no cervical lymphadenopathy. Intraorally the soft tissues of the mouth were healthy with no mucosal lesions detected and no obvious source of infection that could cause the oral dysgeusia. The cracked tongue surface was deemed to be a variation of normal anatomy termed a fissured tongue.

2.3. Investigations {#sec2.3}
-------------------

An orthopantomogram radiograph was completed, which confirmed the absence of dental or bony pathology. Blood investigations, including a full blood count, blood glucose, serum ferritin, folate, and vitamin B12 levels, all resulted as normal.

Due to the reported facial hypoesthesia, magnetic resonance imaging of the head was performed. This identified a large vestibular schwannoma of the left vestibulocochlear nerve (eighth cranial nerve). This measured 2.7 cm by 2.4 cm by 2.3 cm and was located in the left cerebellopontine angle, involving the left internal auditory meatus. There was associated compression of the brainstem and distortion of the fourth ventricle, without hydrocephalus (see Figures [1](#fig1){ref-type="fig"} [](#fig2){ref-type="fig"} [](#fig3){ref-type="fig"}--[4](#fig4){ref-type="fig"}).

2.4. Treatment {#sec2.4}
--------------

The patient was referred to the Ear, Nose, and Throat Team for further management. They identified 45 to 50 decibels of sensorineural hearing loss in the left ear on audiogram. There was also some instability on standing, particularly when the patient\'s eyes were closed. The hypoesthesia of the left trigeminal nerve had worsened, with a constant tingling affecting the maxillary and mandibular divisions and reduced pin prick sensation in these regions.

Treatment options for vestibular schwannoma include monitoring with serial scanning to determine extent of tumour growth, microsurgery to remove or debulk the tumour, or stereotactic radiosurgery \[[@B9]\]. Following discussion at the Skull Base Multidisciplinary Team Meeting, which included a Clinical Oncologist, Neuroradiologist, Ear, Nose, and Throat Surgeon, and Neurosurgeon, a decision was made that microsurgery would be the best treatment option. This was due to the large size of the vestibular schwannoma, the neurological symptoms, and the associated compression of the brain stem. Therefore, the patient underwent surgical excision to remove the tumour and decompress the brainstem. This was undertaken in a joint case with the Ear, Nose, and Throat and Neurosurgery Teams. A translabyrinthine approach was used, which leads to complete hearing loss on the affected side but aims to preserve the facial nerve.

2.5. Outcome {#sec2.5}
------------

Surgical treatment was successful and the histology showed a schwannoma comprising densely cellular Antoni A areas with less densely cellular Antoni B areas. There was no significant mitotic activity or necrosis. Immunohistochemistry showed that it was strongly positive for S100. The conclusion was that it was a benign schwannoma of the left cerebellopontine angle, WHO Grade I. These results were discussed postoperatively at the Skull Base Multidisciplinary Team Meeting and it was agreed that the patient would be followed up by the Neurosurgery Team.

The patient is doing well postoperatively. The aural fullness in the left ear has now completely resolved, and the tinnitus is barely noticeable. The facial hypoesthesia that affected the maxillary and mandibular divisions of the left trigeminal nerve preoperatively has also completely resolved. There was some minor facial weakness, House-Brackmann Grade II, which was present immediately after surgery and has now returned to normal. Furthermore, the oral dysgeusia has improved since the surgery, with an occasional salty taste still noticed. The patient is now awaiting CROS hearing aids to help with his hearing loss on the left side. His balance was severely affected from the surgery but this has now significantly improved.

Postoperative magnetic resonance imaging was performed at six months postoperatively (see Figures [5](#fig5){ref-type="fig"} [](#fig6){ref-type="fig"}--[7](#fig7){ref-type="fig"}). The figures show normal postsurgical changes involving the petrous bone and cerebellopontine angle. The left sided vestibular schwannoma has been resected. There is a cavity in the left middle cerebellar peduncle which is likely to represent an area of perioperative ischaemia. There is a thin cuff of residual tissue anterior to the site of the cerebellopontine angle tumour. The remnant of the schwannoma will be monitored by the Neurosurgery Team with a further magnetic resonance imaging in one year.

3. Discussion {#sec3}
=============

Vestibular schwannomas, also termed acoustic neuromas, are benign tumours of the vestibulocochlear nerve \[[@B10]--[@B17]\]. They arise from the Schwann cells which comprise the myelin sheath surrounding the vestibular branch of the eighth cranial nerve \[[@B17]\] and account for 80--90% of cerebellopontine angle tumours \[[@B10], [@B11], [@B14], [@B15]\]. The aetiology of vestibular schwannoma is unknown. The most common symptoms are unilateral hearing loss, tinnitus, or unsteadiness \[[@B10]--[@B16]\]. As the tumour grows it compresses surrounding intracranial structures. Compression of the trigeminal nerve can lead to facial hypoesthesia, which is found in 7--26% of patients with vestibular schwannoma \[[@B12], [@B18]\], and usually begins in the region of the anterior mandible \[[@B12]\]. In 2.2--17% of patients the facial nerve is affected, due to the close anatomical relationship of the facial nerve to the vestibulocochlear nerve in the region of the cerebellopontine angle \[[@B12], [@B14], [@B18]\]. Pressure on the motor fibres can lead to facial weakness; and involvement of the sensory branch, the nervus intermedius which receives special sensory taste information from the anterior two-thirds of the tongue, via the chorda tympani, can have an impact on taste \[[@B18], [@B19]\]. There are a number of studies reporting facial numbness as the presenting feature of a vestibular schwannoma \[[@B10], [@B11], [@B15]\]. In another case, the patient presented with a burning sensation of the tongue \[[@B17]\], but no other report has described oral dysgeusia as the symptom prompting referral to secondary care.

Facial nerve dysfunction is rarely the presenting symptom of vestibular schwannoma \[[@B16]\]. However, literature shows that, in up to 17% of patients, the facial nerve is affected \[[@B18]\]. When the facial nerve is compressed by the tumour, taste disturbances appear earlier than facial palsy. This is because sensory nerves are more sensitive to compression than motor fibres \[[@B19]\]. A study by Watanabe et al. \[[@B20]\] found that preoperative taste disturbances were found in 28.7% of patients undergoing surgery for a vestibular schwannoma. Another study by Sahu et al. \[[@B19]\] tested 142 patients with vestibular schwannoma and found taste disturbances present in 40.8% of patients preoperatively. Matthies and Samii \[[@B18]\] found that taste disturbances were only reported in 1.8% of 1000 patients diagnosed with vestibular schwannoma, although they did not formally test this and assumed that the actual incidence would be higher. They also established that preoperative taste disturbance was a reliable indicator of facial nerve compromise and impending paresis.

Although oral dysgeusia is rarely the presenting symptom, it is clear that a significant proportion of patients with vestibular schwannoma do experience taste disturbances. It is therefore imperative that for patients presenting with altered taste a detailed history is taken. The history should specifically include questions relating to sensory loss, and the appropriate investigations should be performed to rule out any significant underlying pathology.
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###### 

Possible causes of oral dysgeusia \[[@B1]--[@B5]\].

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Local factors                                                                                                                                                    Dental abscess, candida infection, trauma to the oral cavity, hyposalivation, removable prostheses, and gastric oesophageal reflux disease

                                                                                                                                                                   

  Drugs                                                                                                                                                            Antimicrobials

   Antibacterials: cephalosporins, ciprofloxacin, clarithromycin, clindamycin, co-trimoxazole, doxycycline, imipenem with cilastatin, metronidazole, ofloxacin,\   
   penicillins, trimethoprim, tetracycline, and vancomycin                                                                                                         

   Antivirals: aciclovir, ganciclovir, indinavir, ritonavir, and zidovudine                                                                                        

   Antifungals: fluconazole and griseofulvin                                                                                                                       

  Central nervous system                                                                                                                                           

   Antiparkinsonians: bromocriptine, levodopa, and pergolide                                                                                                       

   Migraine medications: naratriptan and sumatriptan                                                                                                               

   Muscle relaxants: baclofen and methocarbamol                                                                                                                    

   Tricyclic antidepressants: amitriptyline, clomipramine, desipramine, doxepin, imipramine, nortriptyline, and trimipramine                                       

   Selective serotonin reuptake inhibitors: citalopram, fluoxetine, fluvoxamine, and sertraline                                                                    

   Antipsychotics: clozapine, olanzapine, and risperidone                                                                                                          

   Benzodiazepines: alprazolam, clonazepam, flurazepam, and midazolam                                                                                              

   Mood stabilisers: lithium                                                                                                                                       

  Cardiovascular                                                                                                                                                   

   Angiotensin-converting enzyme inhibitors: captopril, enalapril, lisinopril, and perindopril                                                                     

   Beta-adrenoreceptor blockers: labetalol, metoprolol, propranolol, and timolol                                                                                   

   Calcium-channel blockers: amlodipine, diltiazem, and nifedipine                                                                                                 

   Potassium-sparing diuretics: amiloride and triamterene                                                                                                          

   Statins: atorvastatin, fluvastatin, and simvastatin                                                                                                             

   Antiarrhythmics: amiodarone, flecainide, and procainamide                                                                                                       

  Endocrine                                                                                                                                                        

   Diabetic medications: glibenclamide, metformin, and tolbutamide                                                                                                 

  Other                                                                                                                                                            

   Antineoplastics: busulfan, dacarbazine, vinblastine, and vincristine                                                                                            

   Antimalarials: hydroxychloroquine, pyrimethamine, and quinine                                                                                                   

   Bisphosphonates: alendronic acid, etidronic acid, and pamidronic acid                                                                                           

   Bronchodilators: salbutamol and terbutaline                                                                                                                     

   Nonsteroidal anti-inflammatories: celecoxib, diclofenac, ketoprofen, and ketorolac                                                                              

                                                                                                                                                                   

  Systemic disease                                                                                                                                                 Diabetes mellitus, haematinic deficiency (ferritin, folate, or vitamin B12), Sjögren\'s syndrome, Crohn\'s disease, and chronic kidney disease

                                                                                                                                                                   

  Peripheral nervous system                                                                                                                                        Syndromes affecting the facial, glossopharyngeal, or vagal nerves (e.g., Bell\'s palsy) and tumours of the skull base or cerebellopontine angle (meningioma, schwannoma, epidermoid tumour, and brain metastasis)

                                                                                                                                                                   

  Central nervous system                                                                                                                                           Ischaemia, haemorrhage, or demyelination affecting the brainstem, thalamus or cortical components of the gustatory pathway, and temporal lobe epilepsy
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
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